MedKoo Cat#: 407347 | Name: SLC-0111
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SLC-0111, also known as U-104, MST-104 and NSC 213841, is an inhibitor of transmembrane CAIX (Ki = 45.1 nM) and CAXII (Ki = 4.5 nM). Carbonic anhydrase IX (CAIX) is a hypoxia-inducible protein that regulates cellular pH to promote cancer cell survival and invasion in hypoxic microenvironments and is a biomarker of poor prognosis for breast cancer metastasis and survival. CAIX is a critical mediator of the expansion of breast CSCs in hypoxic niches by sustaining the mesenchymal and 'stemness' phenotypes of these cells, making CAIX an important therapeutic target for selectively depleting breast CSCs.

Chemical Structure

SLC-0111
CAS#178606-66-1

Theoretical Analysis

MedKoo Cat#: 407347

Name: SLC-0111

CAS#: 178606-66-1

Chemical Formula: C13H12FN3O3S

Exact Mass: 309.0583

Molecular Weight: 309.32

Elemental Analysis: C, 50.48; H, 3.91; F, 6.14; N, 13.59; O, 15.52; S, 10.36

Price and Availability

Size Price Availability Quantity
25mg USD 135.00 Ready to ship
50mg USD 220.00 Ready to ship
100mg USD 400.00 Ready to ship
200mg USD 690.00 Ready to ship
500mg USD 1,360.00 Ready to ship
1g USD 2,150.00 Ready to ship
2g USD 3,550.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SLC-0111; SLC0111; SLC 0111; MST104; MST-104; MST 104; NSC-213841; NSC213841; NSC 213841; U-104; U104; U 104
IUPAC/Chemical Name
4-(3-(4-fluorophenyl)ureido)benzenesulfonamide
InChi Key
YJQZNWPYLCNRLP-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)
SMILES Code
FC1=CC=C(C=C1)NC(NC2=CC=C(C=C2)S(N)(=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO (10 mg/mL), not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
U-104 (SLC-0111) is a carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively.
In vitro activity:
To evaluate whether SLC-0111 can sensitize cancer cells to conventional chemotherapy, A375-M6 melanoma cells were treated with a sub-lethal dose of Dacarbazine alone or in combination with SLC-0111 to evaluate cell viability with different in vitro assays. As shown by Annexin V/PI assay (Figure 1(a)), A375-M6 treated for 96 h with 50 µM Dacarbazine or 100 µM SLC-0111 alone are not significantly affected in terms of viability, whereas the combined therapy induces significant increase of late apoptosis phase and necrosis. Reference: J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211231/
In vivo activity:
To investigate whether there could be a benefit for addition of SLC-0111 to TMZ (temozolomide) therapy for GBM (glioblastoma) treatment in vivo, GBM PDX cells were subcutaneously implanted into athymic nude immunocompromised mice. After tumor establishment, mice were treated with vehicle, SLC-0111 or TMZ alone, or SLC-0111 and TMZ in combination. SLC-0111 treatment alone was ineffective at delaying tumor growth in vivo in comparison to the vehicle control. However, the combination of SLC-0111 and TMZ delayed tumor recurrence more than either monotherapy (Figure 6A) with complete regression in two mice. Reference: JCI Insight. 2017 Dec 21;2(24):e92928. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752277/
Solvent mg/mL mM comments
Solubility
DMSO 54.0 174.51
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 309.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, Supuran CT, Calorini L. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. doi: 10.1080/14756366.2018.1532419. PMID: 30362384; PMCID: PMC6211231. 2. Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, Spina R, Audia A, Scott SE, Libby CJ, Tran AN, Bevensee MO, Griguer C, Nozell S, Gillespie GY, Nabors B, Bhat KP, Bar EE, Darley-Usmar V, Xu B, Gordon E, Cooper SJ, Dedhar S, Hjelmeland AB. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017 Dec 21;2(24):e92928. doi: 10.1172/jci.insight.92928. PMID: 29263302; PMCID: PMC5752277.
In vitro protocol:
1. Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, Supuran CT, Calorini L. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. doi: 10.1080/14756366.2018.1532419. PMID: 30362384; PMCID: PMC6211231.
In vivo protocol:
1. Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, Spina R, Audia A, Scott SE, Libby CJ, Tran AN, Bevensee MO, Griguer C, Nozell S, Gillespie GY, Nabors B, Bhat KP, Bar EE, Darley-Usmar V, Xu B, Gordon E, Cooper SJ, Dedhar S, Hjelmeland AB. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017 Dec 21;2(24):e92928. doi: 10.1172/jci.insight.92928. PMID: 29263302; PMCID: PMC5752277.
1: Fadaly WAA, Mohamed FEA, Nemr MTM, Sayed AM, Khalil RG, Zidan TH. Novel benzenesulfonamide derivatives as potential selective carbonic anhydrase IX, XII inhibitors with anti-proliferative activity: Design, synthesis and in silico studies. Bioorg Chem. 2024 Oct 10;153:107881. doi: 10.1016/j.bioorg.2024.107881. Epub ahead of print. PMID: 39396453. 2: Giovannuzzi S, Nikitjuka A, Angeli A, Smietana M, Massardi ML, Turati M, Ronca R, Bonardi A, Nocentini A, Ferraroni M, Supuran CT, Winum JY. Benzoxaborinine, New Chemotype for Carbonic Anhydrase Inhibition: Ex Novo Synthesis, Crystallography, In Silico Studies, and Anti-Melanoma Cell Line Activity. J Med Chem. 2024 Oct 24;67(20):18221-18234. doi: 10.1021/acs.jmedchem.4c01516. Epub 2024 Oct 8. PMID: 39378331. 3: Fujita N, Bondoc A, Simoes S, Ishida J, Taccone MS, Luck A, Srikanthan D, Siddaway R, Levine A, Sabha N, Krumholtz S, Kondo A, Arai H, Smith C, McDonald P, Hawkins C, Dedhar S, Rutka J. Combination treatment with histone deacetylase and carbonic anhydrase 9 inhibitors shows therapeutic potential in experimental diffuse intrinsic pontine glioma. Brain Tumor Pathol. 2024 Oct;41(3-4):117-131. doi: 10.1007/s10014-024-00493-w. Epub 2024 Sep 24. PMID: 39316272. 4: Onyilmaz M, Koca M, Ammara A, Degirmenci M, Supuran CT. Isocoumarins incorporating chalcone moieties act as isoform selective tumor-associated carbonic anhydrase inhibitors. Future Med Chem. 2024 Jul 2;16(13):1347-1355. doi: 10.1080/17568919.2024.2350875. Epub 2024 May 28. PMID: 39109432; PMCID: PMC11318696. 5: Liang Q, Zhang S, Liu J, Zhou X, Syamimi Ariffin N, Wei J, Shi C, Ma X, Zhang Y, Huang R. Discovery of novel 1,8-naphthalimide piperazinamide based benzenesulfonamides derivatives as potent carbonic anhydrase IX inhibitors and ferroptosis inducers for the treatment of triple-negative breast cancer. Bioorg Chem. 2024 Sep;150:107596. doi: 10.1016/j.bioorg.2024.107596. Epub 2024 Jun 26. PMID: 38941699. 6: Abbas HS, Nossier ES, El-Manawaty MA, El-Bayaa MN. New sulfonamide-based glycosides incorporated 1,2,3-triazole as cytotoxic agents through VEGFR-2 and carbonic anhydrase inhibitory activity. Sci Rep. 2024 Jun 6;14(1):13028. doi: 10.1038/s41598-024-62864-9. PMID: 38844493; PMCID: PMC11156913. 7: Sharma V, Vats L, Giovannuzzi S, Mohan B, Supuran CT, Sharma PK. In-vitro and in-silico investigations of SLC-0111 hydrazinyl analogs as human carbonic anhydrase I, II, IX, and XII inhibitors. Arch Pharm (Weinheim). 2024 Aug;357(8):e2400157. doi: 10.1002/ardp.202400157. Epub 2024 May 7. PMID: 38713910. 8: Wu S, Zhou X, Li F, Sun W, Zheng Q, Liang D. Novel Anthraquinone-Based Benzenesulfonamide Derivatives and Their Analogues as Potent Human Carbonic Anhydrase Inhibitors with Antitumor Activity: Synthesis, Biological Evaluation, and In Silico Analysis. Int J Mol Sci. 2024 Mar 15;25(6):3348. doi: 10.3390/ijms25063348. PMID: 38542320; PMCID: PMC10969960. 9: Supuran CT. Drug interactions of carbonic anhydrase inhibitors and activators. Expert Opin Drug Metab Toxicol. 2024 Mar;20(3):143-155. doi: 10.1080/17425255.2024.2328152. Epub 2024 Mar 11. PMID: 38450431. 10: Debnath J, Keshamasetthy D, Combs J, Leon K, Vullo D, Chatterjee A, McKenna R, Supuran CT. A comparative study of diaryl urea molecules with and without sulfonamide group on Carbonic anhydrase IX and XII inhibition and its consequence on breast cancer cells. Bioorg Chem. 2024 Apr;145:107192. doi: 10.1016/j.bioorg.2024.107192. Epub 2024 Feb 10. PMID: 38382393. 11: Lolak N, Akocak S, Petreni A, Budak Y, Bozgeyik E, Gurdere MB, Ceylan M, Supuran CT. 1,3-Diaryl Triazenes Incorporating Disulfonamides Show Both Antiproliferative Activity and Effective Inhibition of Tumor-associated Carbonic Anhydrases IX and XII. Anticancer Agents Med Chem. 2024;24(10):755-763. doi: 10.2174/0118715206285326240207045249. PMID: 38362678. 12: McDonald PC, Dedhar S. Co-vulnerabilities of inhibiting carbonic anhydrase IX in ferroptosis-mediated tumor cell death. Front Mol Biosci. 2023 Nov 30;10:1327310. doi: 10.3389/fmolb.2023.1327310. PMID: 38099193; PMCID: PMC10720035. 13: Vats L, Arya P, Kumar R, Giovannuzzi S, Raghav N, Supuran CT, Sharma PK. Keto-bridged dual triazole-linked benzenesulfonamides as potent carbonic anhydrase and cathepsin B inhibitors. Future Med Chem. 2023 Oct;15(20):1843-1863. doi: 10.4155/fmc-2023-0201. Epub 2023 Oct 25. PMID: 37877291. 14: Begines P, Bonardi A, Nocentini A, Gratteri P, Giovannuzzi S, Ronca R, Tavani C, Luisa Massardi M, López Ó, Supuran CT. Design and synthesis of sulfonamides incorporating a biotin moiety: Carbonic anhydrase inhibitory effects, antiproliferative activity and molecular modeling studies. Bioorg Med Chem. 2023 Oct 30;94:117467. doi: 10.1016/j.bmc.2023.117467. Epub 2023 Sep 7. PMID: 37722299. 15: Andreucci E, Biagioni A, Peri S, Versienti G, Cianchi F, Staderini F, Antonuzzo L, Supuran CT, Olivo E, Pasqualini E, Messerini L, Massi D, Lulli M, Ruzzolini J, Peppicelli S, Bianchini F, Schiavone N, Calorini L, Magnelli L, Papucci L. The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane- derived, and platinum-based drugs. Cancer Lett. 2023 Sep 1;571:216338. doi: 10.1016/j.canlet.2023.216338. Epub 2023 Aug 6. PMID: 37549770. 16: Supuran CT. A simple yet multifaceted 90 years old, evergreen enzyme: Carbonic anhydrase, its inhibition and activation. Bioorg Med Chem Lett. 2023 Sep 1;93:129411. doi: 10.1016/j.bmcl.2023.129411. Epub 2023 Jul 26. PMID: 37507055. 17: Elsawi AE, Elbadawi MM, Nocentini A, Almahli H, Giovannuzzi S, Shaldam M, Salem R, Ibrahim TM, Abdel-Aziz HA, Supuran CT, Eldehna WM. 1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities. J Med Chem. 2023 Aug 10;66(15):10558-10578. doi: 10.1021/acs.jmedchem.3c00721. Epub 2023 Jul 27. PMID: 37501287. 18: Grajek J, Poleszczuk J. Carbonic Anhydrase IX Suppression Shifts Partial Response to Checkpoint Inhibitors into Complete Tumor Eradication: Model-Based Investigation. Int J Mol Sci. 2023 Jun 13;24(12):10068. doi: 10.3390/ijms241210068. PMID: 37373220; PMCID: PMC10298206. 19: Eldehna WM, Mohammed EE, Al-Ansary GH, Berrino E, Elbadawi MM, Ibrahim TM, Jaballah MY, Al-Rashood ST, Binjubair FA, Celik M, Nocentini A, Elbarbry FA, Sahin F, Abdel-Aziz HA, Supuran CT, Fares M. Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer. Eur J Med Chem. 2023 Oct 5;258:115538. doi: 10.1016/j.ejmech.2023.115538. Epub 2023 Jun 1. PMID: 37321108. 20: Peerzada MN, Vullo D, Paoletti N, Bonardi A, Gratteri P, Supuran CT, Azam A. Discovery of Novel Hydroxyimine-Tethered Benzenesulfonamides as Potential Human Carbonic Anhydrase IX/XII Inhibitors. ACS Med Chem Lett. 2023 May 8;14(6):810-819. doi: 10.1021/acsmedchemlett.3c00094. PMID: 37312840; PMCID: PMC10258898.